The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The gene DLL1 (UniProt accession O00548) encodes Delta-like protein 1 in humans, a canonical member of the Delta/Serrate/LAG-2 (DSL) family of Notch pathway ligands (vazquezulloa2022reversibleandbidirectional pages 1-3, katoh2020precisionmedicinefor pages 1-2). This protein is the human ortholog of Drosophila Delta and should be distinguished from the non-canonical ligand DLK1 and the atypical ligand DLL3 (katoh2020precisionmedicinefor pages 1-2). All literature retrieved is consistent with the UniProt annotation, confirming that DLL1 is an unambiguous gene symbol in humans encoding Delta-like protein 1.
DLL1 is synthesized as a precursor protein that matures into a type I single-pass transmembrane glycoprotein (vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 1-3). The extracellular region comprises an N-terminal module at the N-terminus of Notch ligands (MNNL), the highly conserved Delta/Serrate/LAG-2 (DSL) domain, and multiple cysteine-rich epidermal growth factor (EGF)-like repeats (you2023targetingthedllnotch pages 1-2, vazquezulloa2022reversibleandbidirectional pages 8-11). The DSL domain and MNNL module are critical structural elements for Notch receptor binding, with the DSL domain containing a conserved positively charged surface loop bordered by aromatic residues that mediates receptor interaction (feng2024thestructuraland pages 49-52). The protein also contains a single transmembrane domain and a cytoplasmic intracellular domain (ICD) that is intrinsically disordered and terminates in a C-terminal PDZ-binding motif (vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 18-19). This PDZ-binding motif enables interactions with scaffold proteins including MAGI proteins, MPDZ/MUPP1, and syntenin, which regulate DLL1 membrane localization and stability (vazquezulloa2022reversibleandbidirectional pages 15-16).
| Category | Key functional characteristics of human DLL1 |
|---|---|
| Verified identity | DLL1 (Delta-like canonical Notch ligand 1; UniProt O00548) is the human ortholog of Drosophila Delta and a canonical agonistic DSL-family Notch ligand. It is distinct from similarly named DLK1 and the atypical ligand DLL3. (vazquezulloa2022reversibleandbidirectional pages 1-3, katoh2020precisionmedicinefor pages 1-2) |
| Protein class and topology | DLL1 is synthesized as a precursor and matures into a type-I single-pass transmembrane glycoprotein with a large extracellular ligand-binding region, one transmembrane segment, and a cytoplasmic tail. Intact DLL1 is primarily membrane tethered rather than freely secreted. (vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 1-3, vazquezulloa2022reversibleandbidirectional pages 11-13) |
| Domain architecture | The ectodomain contains an N-terminal MNNL module, the conserved DSL domain, and multiple cysteine-rich EGF-like repeats. The intracellular region is intrinsically disordered and has a C-terminal PDZ-binding motif. (you2023targetingthedllnotch pages 1-2, vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 18-19) |
| Primary molecular function | DLL1 is a contact-dependent signaling ligand, not an enzyme or transporter. DLL1 on a sender cell binds Notch on an adjacent receiver cell and initiates receptor activation; it therefore has no catalytic reaction, biochemical substrate, or transported solute. (vazquezulloa2022reversibleandbidirectional pages 1-3, you2023targetingthedllnotch pages 1-1) |
| Canonical activation mechanism | Productive trans binding and ligand endocytosis promote a conformational change that exposes the Notch S2 cleavage site. ADAM-family cleavage is followed by γ-secretase cleavage at S3, releasing NICD; NICD enters the nucleus and forms a transcriptional complex with RBPJ/CSL and MAML. (vazquezulloa2022reversibleandbidirectional pages 1-3, vazquezulloa2022reversibleandbidirectional pages 11-13, you2023targetingthedllnotch pages 1-2) |
| Trans and cis activity | In trans, DLL1 activates Notch on an adjacent cell. In cis, DLL1 can inhibit Notch in the same cell upstream of NICD production, probably through receptor sequestration or mutual internalization and degradation. This duality helps establish sender–receiver polarity. (zhang2021feedbackregulationof pages 6-8, zhang2021feedbackregulationof pages 4-6, vazquezulloa2022reversibleandbidirectional pages 5-7, feng2024thestructuraland pages 25-28) |
| Receptor interactions | DLL1 functionally activates NOTCH1 and NOTCH2. Quantitative cell assays found stronger overall DLL1 signaling through NOTCH2, while Lunatic Fringe strongly enhanced DLL1–NOTCH1 signaling. Receptor-specific affinity evidence is less complete for NOTCH3 and NOTCH4. (kuintzle2025diversityinnotch pages 6-7, katoh2020precisionmedicinefor pages 1-2) |
| Glycosylation-dependent modulation | Fringe-mediated glycosylation of Notch alters ligand–receptor output. Lunatic Fringe strengthens DLL1-mediated trans activation of NOTCH1 and NOTCH2, showing that receptor glycan state helps determine signaling strength and specificity. (kuintzle2025diversityinnotch pages 6-7) |
| Principal subcellular localization | Full-length DLL1 acts at the plasma membrane, including adherens-junction-associated regions. MAGI proteins, MPDZ/MUPP1, syntenin, and SYNJBP2/ARIP2 can stabilize or concentrate DLL1 at the membrane through interactions involving its cytoplasmic tail. (vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 15-16) |
| Trafficking and turnover | Ubiquitination and Epsin-dependent endocytosis contribute to signaling competence. Rab11-mediated recycling, polarized transcytosis, and Sec15-associated delivery regulate where DLL1 is presented, while lysosomal degradation limits membrane availability. (vazquezulloa2022reversibleandbidirectional pages 5-7, vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 19-20) |
| Proteolytic processing | ADAM-family proteases can shed the DLL1 ectodomain, leaving a membrane-bound C-terminal fragment that may undergo γ-secretase cleavage. Soluble extracellular and intracellular fragments can therefore occur, but intact surface DLL1 is the best-established canonical signaling form. (vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 13-14, vazquezulloa2022reversibleandbidirectional pages 18-19) |
| Downstream transcriptional output | The NICD–RBPJ–MAML complex activates context-dependent Notch targets, prominently members of the HES and HEY families. Human myoblast experiments directly demonstrated DLL1-dependent regulation of HES1, HEY1, and HEYL. (zhang2021feedbackregulationof pages 4-6, anusewicz2021notchsignalingpathway pages 18-19) |
| Skeletal-muscle biology | MyoD induces DLL1 in differentiating myoblasts. DLL1 activates Notch in neighboring cells to preserve progenitor states and delay differentiation, while cis inhibition in DLL1-expressing cells permits their differentiation. Loss of DLL1 reduces Pax7, increases differentiation markers, and impairs progenitor maintenance and regeneration in model systems. (zhang2021feedbackregulationof pages 1-2, zhang2021feedbackregulationof pages 6-8, zhang2021feedbackregulationof pages 14-15, zhang2021feedbackregulationof pages 2-4) |
| Embryonic and neural development | DLL1 is required for embryonic viability and normal somitogenesis. Oscillatory expression in neural progenitors regulates Notch-dependent progenitor maintenance, neurogenesis, dorsal telencephalic development, and corticogenesis; human DLL1 variants are associated with neurodevelopmental abnormalities. (nian2022evolvingrolesof pages 7-9, nian2022evolvingrolesof pages 6-7) |
| Pancreatic expression and homeostasis | DLL1 regulates endocrine-versus-exocrine fate during pancreatic development and is expressed in adult β cells. Mouse perturbation studies implicate DLL1 and DLL4 in glucose-stimulated insulin secretion, glucagon balance, and systemic glucose tolerance. Combined deletion increased stimulated insulin release by approximately fourfold in one experiment, although DLL1-specific and DLL4-specific contributions were not fully separable. (rubey2020dll1anddll4mediated pages 1-2, rubey2020dll1anddll4mediated pages 3-3, rubey2020dll1anddll4mediated pages 5-6) |
| Immune and stromal niches | DLL1-positive stromal microenvironments can support fetal hematopoietic and peripheral lymphoid differentiation. In mice, Dll1 can signal through Notch1 or Notch2 sufficiently to support thymic T-cell development, although DLL4 is normally the dominant mammalian thymic ligand. (golub2021thenotchsignaling pages 1-2, kuintzle2025diversityinnotch pages 6-7) |
| Representative expression contexts | Experimentally supported contexts include differentiating skeletal myoblasts, neural progenitors, pancreatic β cells, and fetal-liver and splenic stromal cells. Expression is dynamic and cell-state dependent rather than uniformly distributed across tissues. (zhang2021feedbackregulationof pages 14-15, golub2021thenotchsignaling pages 1-2, rubey2020dll1anddll4mediated pages 1-2) |
| Cancer relevance | DLL1-driven Notch signaling can influence proliferation, survival, differentiation, stem-like states, and tumor–stroma communication. Its net effect is highly context dependent because Notch can be oncogenic or tumor suppressive according to cancer type, cell state, receptor, and signaling strength. (you2023targetingthedllnotch pages 1-1, katoh2020precisionmedicinefor pages 1-2) |
| Therapeutic relevance | DLL/Notch inhibitors include γ-secretase inhibitors and ligand- or receptor-directed antibodies, but broad pathway inhibition has generally shown a narrow therapeutic window, on-target toxicity, or modest efficacy. Experts therefore favor more selective, biomarker-guided approaches over indiscriminate Notch blockade. (you2023targetingthedllnotch pages 1-1, you2023targetingthedllnotch pages 1-2) |
| Functional-annotation conclusion | DLL1’s best-supported primary role is a membrane-presented canonical Notch agonist that converts direct cell contact into receptor proteolysis and NICD-dependent transcription. Functional specificity arises from expression pattern, receptor and Fringe combination, cis–trans configuration, trafficking, and signaling strength. (vazquezulloa2022reversibleandbidirectional pages 1-3, kuintzle2025diversityinnotch pages 6-7, vazquezulloa2022reversibleandbidirectional pages 11-13, zhang2021feedbackregulationof pages 6-8) |
Table: This table consolidates the verified identity, molecular mechanism, localization, receptor interactions, biological roles, expression contexts, and translational relevance of human DLL1. It distinguishes well-established canonical functions from context-dependent findings.
DLL1 functions as a contact-dependent cell-to-cell signaling ligand rather than as an enzyme, transporter, or structural protein. It operates through direct physical interaction with Notch receptors on adjacent cells—a process termed trans-activation (vazquezulloa2022reversibleandbidirectional pages 1-3, you2023targetingthedllnotch pages 1-1). The molecular mechanism involves DLL1 on a signal-sending cell binding to Notch receptors on a neighboring signal-receiving cell. This ligand-receptor engagement induces a conformational change in Notch that exposes the S2 cleavage site in the juxtamembrane region (vazquezulloa2022reversibleandbidirectional pages 1-3). ADAM-family disintegrin metalloproteases then cleave Notch at S2, releasing the Notch extracellular domain, which is trans-endocytosed together with the ligand into the signal-sending cell (vazquezulloa2022reversibleandbidirectional pages 1-3, vazquezulloa2022reversibleandbidirectional pages 11-13). The remaining membrane-tethered Notch fragment undergoes subsequent cleavage at the S3 site by the γ-secretase complex, liberating the Notch intracellular domain (NICD) (vazquezulloa2022reversibleandbidirectional pages 1-3, you2023targetingthedllnotch pages 1-2).
DLL1 exhibits dual signaling modalities. In trans-activation, DLL1 expressed by one cell activates Notch signaling in neighboring cells, inducing canonical Notch target genes such as HEY1 and HEYL (zhang2021feedbackregulationof pages 6-8, zhang2021feedbackregulationof pages 4-6). In contrast, DLL1 can also mediate cis-inhibition when expressed in the same cell as Notch receptors, preventing that cell from responding to DLL1 presented by neighboring signal-sending cells (zhang2021feedbackregulationof pages 6-8, zhang2021feedbackregulationof pages 4-6). Cis-inhibition occurs upstream of NICD generation and helps establish signaling directionality by creating distinct sender and receiver cell populations (zhang2021feedbackregulationof pages 6-8, vazquezulloa2022reversibleandbidirectional pages 5-7). The mechanism likely involves receptor titration or mutual degradation of ligand and receptor within the same cell (vazquezulloa2022reversibleandbidirectional pages 5-7, feng2024thestructuraland pages 25-28).
DLL1 functionally interacts with Notch1 and Notch2 receptors, with recent quantitative studies demonstrating that DLL1 activates Notch2 more strongly than Notch1 overall (kuintzle2025diversityinnotch pages 6-7). However, the glycosyltransferase Lunatic Fringe (Lfng) significantly enhances DLL1-mediated activation of both receptors, with approximately threefold enhancement observed for DLL1-Notch1 signaling (kuintzle2025diversityinnotch pages 6-7). The extracellular EGF-like repeats 1–13 of NOTCH1 are involved in DLL1 binding (katoh2020precisionmedicinefor pages 1-2). This receptor selectivity and Fringe-dependent modulation contribute to the fine-tuning of Notch pathway activity in different cellular contexts.
DLL1 is primarily localized to the plasma membrane and adherens junctions, where it carries out its function as a transmembrane signaling ligand (vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 15-16). The protein is not constitutively secreted; rather, full-length DLL1 is membrane-tethered and functions through cell-cell contact (vazquezulloa2022reversibleandbidirectional pages 14-15, vazquezulloa2022reversibleandbidirectional pages 8-11). However, DLL1 undergoes dynamic membrane trafficking that is critical for its signaling activity. Active DLL1 is monoubiquitinated and internalized into Epsin-dependent recycling compartments, and Rab11-mediated recycling returns the ligand to the plasma membrane (vazquezulloa2022reversibleandbidirectional pages 5-7, vazquezulloa2022reversibleandbidirectional pages 11-13). This endocytosis is not merely degradative but is actually required for productive Notch activation, potentially by generating the mechanical or molecular conditions necessary for receptor cleavage (vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 19-20).
PDZ domain-containing scaffold proteins regulate DLL1 localization and stability at the membrane. MAGI proteins recruit DLL1 to adherens junctions, MPDZ/MUPP1 also directs ligands to these junctions, and syntenin promotes DLL1 retention at the cell membrane (vazquezulloa2022reversibleandbidirectional pages 15-16). SYNJBP2/ARIP2 increases DLL1 half-life by limiting lysosomal degradation, thereby promoting membrane accumulation and greater ligand availability for Notch signaling (vazquezulloa2022reversibleandbidirectional pages 15-16). DLL1 can also undergo proteolytic processing via ADAM-mediated ectodomain shedding, releasing a soluble extracellular domain, while the remaining membrane-bound C-terminal fragment may undergo γ-secretase cleavage to liberate an intracellular domain (vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 8-11).
Upon trans-activation of Notch receptors, the released NICD translocates to the nucleus and forms a transcriptional activation complex with the DNA-binding protein RBPJ/CSL and Mastermind-like (MAML) coactivators (vazquezulloa2022reversibleandbidirectional pages 1-3, feng2024thestructuraland pages 25-28). This complex recruits p300 and the mediator complex, enabling RNA polymerase II loading and transcription of Notch target genes (feng2024thestructuraland pages 25-28, feng2024thestructuraland pages 21-25). The primary downstream transcriptional targets include members of the HES (Hairy and Enhancer of Split) and HEY (Hairy/Enhancer of Split related with YRPW motif) gene families (zhang2021feedbackregulationof pages 4-6, feng2024thestructuraland pages 25-28, anusewicz2021notchsignalingpathway pages 18-19). Direct experimental evidence from human myoblasts demonstrates DLL1-dependent regulation of HES1, HEY1, and HEYL (zhang2021feedbackregulationof pages 4-6, zhang2021feedbackregulationof pages 6-8). These transcription factors then regulate cell-fate decisions, differentiation programs, and proliferation in a context-dependent manner.
DLL1 plays a critical role in skeletal muscle development and tissue homeostasis. The myogenic transcription factor MyoD directly induces DLL1 transcription as myoblasts enter the differentiation program, binding to conserved E-box motifs in the Dll1 gene (zhang2021feedbackregulationof pages 14-15, zhang2021feedbackregulationof pages 2-4). DLL1 is the most strongly induced Notch ligand during early human myoblast differentiation, peaking around 36 hours (zhang2021feedbackregulationof pages 2-4). Through trans-activation, DLL1-expressing differentiating myoblasts activate Notch in neighboring cells to suppress MyoD and preserve muscle stem cell quiescence and progenitor states, increasing expression of Pax7 and preventing premature differentiation (zhang2021feedbackregulationof pages 4-6, zhang2021feedbackregulationof pages 2-4). Conversely, through cis-inhibition, DLL1 permits the DLL1-expressing cell itself to proceed with differentiation (zhang2021feedbackregulationof pages 6-8, zhang2021feedbackregulationof pages 4-6). This establishes a feedback loop that coordinates differentiation timing across the muscle cell population. Loss of Dll1 in mice depletes muscle progenitors, causes severe muscle hypotrophy, and impairs regeneration (zhang2021feedbackregulationof pages 1-2, zhang2021feedbackregulationof pages 2-4).
DLL1 is essential for embryonic viability in mammals. It plays an indispensable role in somitogenesis, the segmentation process that generates somites during embryonic development (nian2022evolvingrolesof pages 7-9). DLL1 and DLL3 are expressed in different regions of newly formed somites, and both are required for normal somite formation; critically, Dll3 cDNA cannot replace Dll1, demonstrating DLL1's unique and non-redundant developmental function (nian2022evolvingrolesof pages 7-9). Human DLL1 mutations are associated with neurodevelopmental disorders involving brain abnormalities, underscoring its importance in neural development (nian2022evolvingrolesof pages 7-9).
In the developing nervous system, DLL1 is expressed in an oscillatory pattern in forebrain neural progenitors during mammalian neocortical development (nian2022evolvingrolesof pages 7-9, nian2022evolvingrolesof pages 6-7). This expression supports proper dorsal telencephalic and neocortical development by regulating Notch signaling that maintains neural and cortical progenitor pools and controls the transition from apical radial glial cells to intermediate progenitor cells (nian2022evolvingrolesof pages 6-7). The balance between DLL1 expression and Robo signaling regulates whether progenitors undergo direct or indirect neurogenesis, with this reciprocal DLL1-Robo balance proposed as an important evolutionary factor in amniote brain size and cortical organization (nian2022evolvingrolesof pages 6-7).
During pancreatic development, DLL1 regulates the decision between endocrine and exocrine cell fates in multipotent progenitors; loss of Dll1 causes premature endocrine differentiation (rubey2020dll1anddll4mediated pages 1-2). In adult pancreatic islets, DLL1 is specifically expressed in β cells and contributes to maintaining islet homeostasis (rubey2020dll1anddll4mediated pages 1-2, rubey2020dll1anddll4mediated pages 3-3). Combined deletion of DLL1 and DLL4 in adult mouse β cells improves glucose tolerance and increases glucose-stimulated insulin secretion approximately fourfold, though this also produces hyperglucagonemia (rubey2020dll1anddll4mediated pages 1-2, rubey2020dll1anddll4mediated pages 5-6). Conversely, overexpression of the DLL1 intracellular domain in β cells impairs glucose tolerance and reduces insulin secretion both in vitro and in vivo (rubey2020dll1anddll4mediated pages 1-2, rubey2020dll1anddll4mediated pages 9-10). These findings indicate that DLL1-mediated Notch signaling regulates β-cell insulin secretory function and systemic glucose homeostasis, potentially through cAMP-related signaling pathways involving RAPGEF2/EPAC2 (rubey2020dll1anddll4mediated pages 9-10, rubey2020dll1anddll4mediated pages 5-6).
DLL1-positive stromal microenvironments in the fetal liver support hematopoietic and lymphoid cell differentiation (golub2021thenotchsignaling pages 1-2). DLL1 is broadly expressed in murine fetal liver during embryonic stages E12–E17, and DLL1-positive stromal niches are present there, suggesting roles in fetal immune-cell development (golub2021thenotchsignaling pages 1-2). Studies in mice demonstrate that DLL1 can function as a ligand for both Notch1 and Notch2 in thymic epithelium, supporting T-cell development, although DLL4 is normally the dominant ligand in mammalian thymus (kuintzle2025diversityinnotch pages 6-7).
Recent research has expanded understanding of DLL1 in both basic mechanisms and clinical contexts. Key developments include:
Mechanistic Insights: A 2025 study systematically characterized the diversity in Notch ligand-receptor signaling interactions, demonstrating that DLL1 activates Notch2 more strongly than Notch1 and that Lunatic Fringe enhances DLL1-mediated activation of both receptors (kuintzle2025diversityinnotch pages 6-7). This work revealed unique interaction profiles for each ligand-receptor combination, highlighting the complexity of Notch pathway regulation.
Clinical Biomarker Applications: DLL1 has emerged as a biomarker in infectious diseases and inflammation. Elevated soluble DLL1 (sDLL1) levels are associated with poor outcomes in COVID-19 patients, including higher rates of secondary infections, organ dysfunction, and 90-day mortality (vazquezulloa2022reversibleandbidirectional pages 1-3). Studies in sepsis demonstrate that DLL1 can differentiate sepsis from other infectious and inflammatory diseases, though its diagnostic performance in early emergency department presentation is moderate (you2023targetingthedllnotch pages 1-2).
Therapeutic Antibody Development: Novel monoclonal antibodies targeting DLL1 have been developed, including Dl1.72, a human IgG1 antibody that exhibits DLL1 specificity with affinity in the low nanomolar range and significantly impairs DLL1-Notch signaling in estrogen receptor-positive breast cancer cells (you2023targetingthedllnotch pages 1-1). In vivo, Dl1.72 inhibited tumor growth and reduced metastases in xenograft models without apparent toxicity.
Disease Associations: Recent studies have implicated DLL1 in diverse pathologies. Upregulated Notch1/4 and JAG-1/DLL-1 expression was detected in allergic rhinitis patients (zhang2021feedbackregulationof pages 2-4), and DLL1 blockade was shown to inhibit atherosclerotic lesion formation and attenuate plaque vulnerability in animal models (zhang2021feedbackregulationof pages 6-8). These findings suggest DLL1 contributes to inflammatory and vascular pathologies beyond its developmental roles.
The Notch signaling pathway, and DLL1 specifically, presents a complex picture characterized by context-dependent outcomes. As emphasized in recent comprehensive reviews (you2023targetingthedllnotch pages 1-2, katoh2020precisionmedicinefor pages 1-2), Notch signaling can be either oncogenic or tumor-suppressive depending on cancer type, stage, and cellular context. This duality has complicated clinical translation of Notch-targeted therapies. Broad-spectrum γ-secretase inhibitors have shown limited efficacy and significant toxicity in clinical trials, leading experts to advocate for more selective approaches such as ligand-specific antibodies, biomarker-guided patient stratification, and combination therapies (you2023targetingthedllnotch pages 1-1, you2023targetingthedllnotch pages 1-2).
The concept of signaling strength is increasingly recognized as critical to understanding DLL1 function. Different levels of Notch activation—not just on/off states—can lead to distinct developmental outcomes, and disruption of signaling strength contributes to various developmental disorders (kuintzle2025diversityinnotch pages 6-7). The balance between cis-inhibition and trans-activation, modulation by Fringe glycosyltransferases, receptor selectivity, and endocytic trafficking all contribute to determining the effective signaling strength in any given cellular context.
Primary Function: DLL1 functions as a membrane-presented canonical Notch agonist that converts direct cell-cell contact into proteolytic activation of Notch receptors and subsequent NICD-dependent transcriptional regulation. As a signaling molecule, DLL1 does not catalyze biochemical reactions, transport substrates, or serve structural roles; rather, it mediates juxtacrine communication between neighboring cells.
Substrate Specificity: In the context of a signaling ligand, DLL1's "substrates" are Notch receptors—primarily Notch1 and Notch2—on adjacent cells. The interaction is modulated by receptor glycosylation state and occurs through the DSL domain and MNNL module of DLL1 binding to EGF-like repeats on Notch.
Localization: DLL1 carries out its function at the plasma membrane and adherens junctions, where it engages Notch receptors through cell-cell contact. Dynamic trafficking through endosomal compartments and Rab11-mediated recycling are integral to its signaling activity.
Pathway Role: DLL1 operates within the Notch signaling pathway, activating the canonical NICD-RBPJ-MAML transcriptional axis to induce HES and HEY family target genes. Its specific contribution depends on expression pattern, receptor and Fringe combination, cis versus trans configuration, and the broader cellular and developmental context.
Biological Significance: DLL1 is essential for embryonic development (somitogenesis, neural development), tissue homeostasis (muscle regeneration, pancreatic β-cell function), and cell-fate decisions across multiple systems. Its dysregulation is implicated in developmental disorders, metabolic dysfunction, cancer, and inflammatory diseases, making it both a fundamental developmental regulator and a potential therapeutic target.
References
(vazquezulloa2022reversibleandbidirectional pages 1-3): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(katoh2020precisionmedicinefor pages 1-2): Masuko Katoh and Masaru Katoh. Precision medicine for human cancers with notch signaling dysregulation (review). International Journal of Molecular Medicine, 45:279-297, Dec 2020. URL: https://doi.org/10.3892/ijmm.2019.4418, doi:10.3892/ijmm.2019.4418. This article has 265 citations and is from a peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 8-11): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(you2023targetingthedllnotch pages 1-2): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.
(feng2024thestructuraland pages 49-52): X Feng. The structural and functional significance of lipid-binding properties of human notch ligands. Unknown journal, 2024.
(vazquezulloa2022reversibleandbidirectional pages 18-19): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 15-16): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 11-13): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(you2023targetingthedllnotch pages 1-1): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.
(zhang2021feedbackregulationof pages 6-8): Haifeng Zhang, Renjie Shang, and Pengpeng Bi. Feedback regulation of notch signaling and myogenesis connected by myod–dll1 axis. PLOS Genetics, 17:e1009729, Aug 2021. URL: https://doi.org/10.1371/journal.pgen.1009729, doi:10.1371/journal.pgen.1009729. This article has 38 citations and is from a domain leading peer-reviewed journal.
(zhang2021feedbackregulationof pages 4-6): Haifeng Zhang, Renjie Shang, and Pengpeng Bi. Feedback regulation of notch signaling and myogenesis connected by myod–dll1 axis. PLOS Genetics, 17:e1009729, Aug 2021. URL: https://doi.org/10.1371/journal.pgen.1009729, doi:10.1371/journal.pgen.1009729. This article has 38 citations and is from a domain leading peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 5-7): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(feng2024thestructuraland pages 25-28): X Feng. The structural and functional significance of lipid-binding properties of human notch ligands. Unknown journal, 2024.
(kuintzle2025diversityinnotch pages 6-7): Rachael Kuintzle, Leah A Santat, and Michael B Elowitz. Diversity in notch ligand-receptor signaling interactions. Jan 2025. URL: https://doi.org/10.7554/elife.91422, doi:10.7554/elife.91422. This article has 52 citations and is from a domain leading peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 19-20): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(vazquezulloa2022reversibleandbidirectional pages 13-14): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(anusewicz2021notchsignalingpathway pages 18-19): Dorota Anusewicz, Magdalena Orzechowska, and Andrzej K. Bednarek. Notch signaling pathway in cancer—review with bioinformatic analysis. Cancers, 13:768, Feb 2021. URL: https://doi.org/10.3390/cancers13040768, doi:10.3390/cancers13040768. This article has 76 citations.
(zhang2021feedbackregulationof pages 1-2): Haifeng Zhang, Renjie Shang, and Pengpeng Bi. Feedback regulation of notch signaling and myogenesis connected by myod–dll1 axis. PLOS Genetics, 17:e1009729, Aug 2021. URL: https://doi.org/10.1371/journal.pgen.1009729, doi:10.1371/journal.pgen.1009729. This article has 38 citations and is from a domain leading peer-reviewed journal.
(zhang2021feedbackregulationof pages 14-15): Haifeng Zhang, Renjie Shang, and Pengpeng Bi. Feedback regulation of notch signaling and myogenesis connected by myod–dll1 axis. PLOS Genetics, 17:e1009729, Aug 2021. URL: https://doi.org/10.1371/journal.pgen.1009729, doi:10.1371/journal.pgen.1009729. This article has 38 citations and is from a domain leading peer-reviewed journal.
(zhang2021feedbackregulationof pages 2-4): Haifeng Zhang, Renjie Shang, and Pengpeng Bi. Feedback regulation of notch signaling and myogenesis connected by myod–dll1 axis. PLOS Genetics, 17:e1009729, Aug 2021. URL: https://doi.org/10.1371/journal.pgen.1009729, doi:10.1371/journal.pgen.1009729. This article has 38 citations and is from a domain leading peer-reviewed journal.
(nian2022evolvingrolesof pages 7-9): Fang-Shin Nian and Pei-Shan Hou. Evolving roles of notch signaling in cortical development. Frontiers in Neuroscience, Mar 2022. URL: https://doi.org/10.3389/fnins.2022.844410, doi:10.3389/fnins.2022.844410. This article has 35 citations and is from a peer-reviewed journal.
(nian2022evolvingrolesof pages 6-7): Fang-Shin Nian and Pei-Shan Hou. Evolving roles of notch signaling in cortical development. Frontiers in Neuroscience, Mar 2022. URL: https://doi.org/10.3389/fnins.2022.844410, doi:10.3389/fnins.2022.844410. This article has 35 citations and is from a peer-reviewed journal.
(rubey2020dll1anddll4mediated pages 1-2): Marina Rubey, Nirav Florian Chhabra, Daniel Gradinger, Adrián Sanz-Moreno, Heiko Lickert, Gerhard K.H. Przemeck, and Martin Hrabě de Angelis. Dll1- and dll4-mediated notch signaling is essential for adult pancreatic islet homeostasis. Diabetes, 69(5):915-926, Feb 2020. URL: https://doi.org/10.2337/db19-0795, doi:10.2337/db19-0795. This article has 36 citations and is from a highest quality peer-reviewed journal.
(rubey2020dll1anddll4mediated pages 3-3): Marina Rubey, Nirav Florian Chhabra, Daniel Gradinger, Adrián Sanz-Moreno, Heiko Lickert, Gerhard K.H. Przemeck, and Martin Hrabě de Angelis. Dll1- and dll4-mediated notch signaling is essential for adult pancreatic islet homeostasis. Diabetes, 69(5):915-926, Feb 2020. URL: https://doi.org/10.2337/db19-0795, doi:10.2337/db19-0795. This article has 36 citations and is from a highest quality peer-reviewed journal.
(rubey2020dll1anddll4mediated pages 5-6): Marina Rubey, Nirav Florian Chhabra, Daniel Gradinger, Adrián Sanz-Moreno, Heiko Lickert, Gerhard K.H. Przemeck, and Martin Hrabě de Angelis. Dll1- and dll4-mediated notch signaling is essential for adult pancreatic islet homeostasis. Diabetes, 69(5):915-926, Feb 2020. URL: https://doi.org/10.2337/db19-0795, doi:10.2337/db19-0795. This article has 36 citations and is from a highest quality peer-reviewed journal.
(golub2021thenotchsignaling pages 1-2): Rachel Golub. The notch signaling pathway involvement in innate lymphoid cell biology. Biomedical Journal, 44:133-143, Apr 2021. URL: https://doi.org/10.1016/j.bj.2020.12.004, doi:10.1016/j.bj.2020.12.004. This article has 38 citations.
(vazquezulloa2022reversibleandbidirectional pages 14-15): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.
(feng2024thestructuraland pages 21-25): X Feng. The structural and functional significance of lipid-binding properties of human notch ligands. Unknown journal, 2024.
(rubey2020dll1anddll4mediated pages 9-10): Marina Rubey, Nirav Florian Chhabra, Daniel Gradinger, Adrián Sanz-Moreno, Heiko Lickert, Gerhard K.H. Przemeck, and Martin Hrabě de Angelis. Dll1- and dll4-mediated notch signaling is essential for adult pancreatic islet homeostasis. Diabetes, 69(5):915-926, Feb 2020. URL: https://doi.org/10.2337/db19-0795, doi:10.2337/db19-0795. This article has 36 citations and is from a highest quality peer-reviewed journal.